NasdaqGS - Nasdaq Real Time Price USD
Mineralys Therapeutics, Inc. (MLYS)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 4:02 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 6 |
| Avg. Estimate | -0.83 | -0.86 | -3.2 | -3.4 |
| Low Estimate | -0.93 | -0.98 | -3.48 | -3.66 |
| High Estimate | -0.66 | -0.63 | -2.59 | -3.03 |
| Year Ago EPS | -0.57 | -0.61 | -1.99 | -3.2 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.76 | -0.82 | -0.67 | -0.7 |
| EPS Actual | -0.57 | -0.61 | -0.7 | -0.83 |
| Difference | 0.19 | 0.21 | -0.03 | -0.13 |
| Surprise % | 25.00% | 25.60% | -4.50% | -18.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.83 | -0.86 | -3.2 | -3.4 |
| 7 Days Ago | -0.83 | -0.86 | -3.2 | -3.4 |
| 30 Days Ago | -0.83 | -0.86 | -3.2 | -3.4 |
| 60 Days Ago | -0.83 | -0.86 | -3.2 | -3.4 |
| 90 Days Ago | -0.74 | -0.75 | -2.92 | -3.09 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MLYS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -45.60% | -- | -- | 3.70% |
| Next Qtr. | -41.00% | -- | -- | 7.90% |
| Current Year | -60.80% | -- | -- | 2.50% |
| Next Year | -6.20% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 57.50% | -- | -- | 11.88% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/15/2024 |
| Initiated | HC Wainwright & Co.: Buy | 7/10/2024 |
| Initiated | Goldman Sachs: Buy | 4/2/2024 |
| Maintains | Credit Suisse: Outperform to Outperform | 8/8/2023 |
| Reiterates | Credit Suisse: Outperform to Outperform | 5/16/2023 |
| Maintains | Credit Suisse: Outperform | 3/16/2023 |
Related Tickers
PEPG PepGen Inc.
8.94
+0.79%
TCRX TScan Therapeutics, Inc.
5.37
+2.09%
DNTH Dianthus Therapeutics, Inc.
29.05
+3.64%
ORIC ORIC Pharmaceuticals, Inc.
9.45
+3.28%
ELVN Enliven Therapeutics, Inc.
29.00
+3.50%
OLMA Olema Pharmaceuticals, Inc.
12.43
+0.97%
ATXS Astria Therapeutics, Inc.
11.46
-2.55%
NMRA Neumora Therapeutics, Inc.
16.49
-2.77%
CRGX CARGO Therapeutics, Inc.
22.22
+2.40%
SYRE Spyre Therapeutics, Inc.
32.76
0.00%